New scope could help rectal cancer patients avoid surgery

NCT ID NCT06189846

Completed Knowledge-focused Sponsor: Bordeaux Colorectal Institute Academy Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study tested a special scope called LUMENEYE to see if it can better measure how well rectal cancer responds to chemotherapy and radiation. 82 patients who were good candidates for organ preservation took part. The goal was to see if the scope could accurately identify complete or near-complete tumor shrinkage, helping doctors decide who might avoid surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Amsterdam UMC

Amsterdam, Netherlands
CHU de ROUEN

Rouen, France
Clinique Tivoli-Ducos - Bordeaux Colorectal Institute

Bordeaux, France
Humanitas Research Hospital

Milan, Italy
Hôpital Européen de Marseille

Marseille, France
Hôpital Saint-Antoine - APHP

Paris, France
Imperial College London

London, United Kingdom
University Hospital Vall D'Hebron

Barcelona, Spain

Conditions

Explore the condition pages connected to this study.

RECTAL CANCER